186 related articles for article (PubMed ID: 28434315)
1. Diflunisal compassive use in transthyretin hereditary amyloid polyneuropathy: report of a first Spanish experience.
Azorín SE; Cabib CE; Campistol JM
Amyloid; 2017 Mar; 24(sup1):105-106. PubMed ID: 28434315
[No Abstract] [Full Text] [Related]
2. The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition.
Wixner J; Westermark P; Ihse E; Pilebro B; Lundgren HE; Anan I
Amyloid; 2019; 26(sup1):39-40. PubMed ID: 31343354
[No Abstract] [Full Text] [Related]
3. Disease-Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy.
Ueda M; Misumi Y; Nomura T; Tasaki M; Yamakawa S; Obayashi K; Yamashita T; Ando Y
Ann Neurol; 2024 Feb; 95(2):230-236. PubMed ID: 38053464
[TBL] [Abstract][Full Text] [Related]
4. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
Sekijima Y
Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
[TBL] [Abstract][Full Text] [Related]
5. Antibody therapy for transthyretin-related hereditary amyloid polyneuropathy: another therapeutic option.
Ando Y; Ueda M
Amyloid; 2017 Mar; 24(sup1):113-114. PubMed ID: 28434350
[No Abstract] [Full Text] [Related]
6. Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area.
Takahashi R; Ono K; Shibata S; Nakamura K; Komatsu J; Ikeda Y; Ikeda T; Samuraki M; Sakai K; Iwasa K; Kayano D; Yamada M
J Neurol Sci; 2014 Oct; 345(1-2):231-5. PubMed ID: 25060417
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases.
Cruz MW; Schmidt H; Botteman MF; Carter JA; Chopra AS; Stewart M; Hopps M; Fallet S; Amass L
Amyloid; 2017 Mar; 24(sup1):109-110. PubMed ID: 28434345
[No Abstract] [Full Text] [Related]
8. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.
Klimtchuk ES; Prokaeva T; Frame NM; Abdullahi HA; Spencer B; Dasari S; Cui H; Berk JL; Kurtin PJ; Connors LH; Gursky O
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6428-E6436. PubMed ID: 29941560
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
Buxbaum JN
Amyloid; 2019 Jun; 26(2):55-65. PubMed ID: 30907141
[TBL] [Abstract][Full Text] [Related]
10. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.
Berk JL; Suhr OB; Obici L; Sekijima Y; Zeldenrust SR; Yamashita T; Heneghan MA; Gorevic PD; Litchy WJ; Wiesman JF; Nordh E; Corato M; Lozza A; Cortese A; Robinson-Papp J; Colton T; Rybin DV; Bisbee AB; Ando Y; Ikeda S; Seldin DC; Merlini G; Skinner M; Kelly JW; Dyck PJ;
JAMA; 2013 Dec; 310(24):2658-67. PubMed ID: 24368466
[TBL] [Abstract][Full Text] [Related]
11. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.
Siddiqi OK; Mints YY; Berk JL; Connors L; Doros G; Gopal DM; Kataria S; Lohrmann G; Pipilas AR; Ruberg FL
Amyloid; 2022 Jun; 29(2):71-78. PubMed ID: 35083944
[TBL] [Abstract][Full Text] [Related]
12. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
13. Effect of diflunisal on clusterin levels in ATTRwt amyloidosis.
Torres-Arancivia C; Connors LH
Amyloid; 2019; 26(sup1):49-50. PubMed ID: 31343317
[No Abstract] [Full Text] [Related]
14. Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis.
Patel RK; Fontana M; Hawkins PN; Gillmore J
Amyloid; 2021 Dec; 28(4):269-270. PubMed ID: 33945356
[No Abstract] [Full Text] [Related]
15. Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review.
Schmidt H; Cruz MW; Botteman MF; Carter JA; Chopra A; Stewart M; Hopps M; Fallet S; Amass L
Amyloid; 2017 Mar; 24(sup1):111-112. PubMed ID: 28434339
[No Abstract] [Full Text] [Related]
16. Two cases of late onset familial amyloid polyneuropathy with a Glu61Lys transthyretin variant.
Nakano Y; Tadokoro K; Ohta Y; Sato K; Takemoto M; Hishikawa N; Yamashita T; Yamashita T; Ando Y; Abe K
J Neurol Sci; 2018 Jul; 390():22-25. PubMed ID: 29801893
[No Abstract] [Full Text] [Related]
17. Common clinicopathological features in late-onset hereditary transthyretin amyloidosis (Ala97Gly, Val94Gly and Val30Met).
Koike H; Nakamura T; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Yasuda T; Mukai E; Date Y; Shiomi K; Nakazato M; Katsuno M; Sobue G
Amyloid; 2019; 26(sup1):24-25. PubMed ID: 31343348
[No Abstract] [Full Text] [Related]
18. Transthyretin-type cerebral amyloid angiopathy: a serious complication in post-transplant patients with familial amyloid polyneuropathy.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):124. PubMed ID: 25112309
[No Abstract] [Full Text] [Related]
19. Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange.
Tsai FJ; Nelson LT; Kline GM; Jäger M; Berk JL; Sekijima Y; Powers ET; Kelly JW
Amyloid; 2023 Jun; 30(2):220-224. PubMed ID: 36444793
[TBL] [Abstract][Full Text] [Related]
20. The Diflunisal Trial: study accrual and drug tolerance.
Berk JL; Suhr OB; Sekijima Y; Yamashita T; Heneghan M; Zeldenrust SR; Ando Y; Ikeda S; Gorevic P; Merlini G; Kelly JW; Skinner M; Bisbee AB; Dyck PJ; Obici L;
Amyloid; 2012 Jun; 19 Suppl 1():37-8. PubMed ID: 22551208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
